Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PCSK9 Mechanism Lends Confidence Ahead Of Outcomes Data

Executive Summary

With a well-defined mechanism of action and positive post hoc outcomes data, PCSK9 inhibitors possess a profile that raises the bar for other non-statin classes – CETP in particular.

You may also be interested in...



Pfizer’s Bococizumab Discontinuation Increases Uncertainty For Other PCSK9s

Pfizer discontinued its late-stage PCSK9 inhibitor bococizumab after seeing 52-week data showing an unanticipated attenuation of LDL-cholesterol lowering and a higher level of immunogenicity, raising questions about what the impact could be for Amgen’s Repatha and Sanofi/Regeneron’s Praluent.

Where Cholesterol Surrogates Stand After ACC '16

Failure of another CETP inhibitor – Lilly’s evacetrapib – despite robust LDL-lowering raises more doubt about surrogates, yet doesn’t put too much of a damper on PCSK9 inhibitors at the annual American College of Cardiology meeting. Statins get another boost just ahead of entry of Crestor generics.

PCSK9 Sponsors, Payers In The Ring At ACC

Cardiologists bemoaned high cost of new drugs and high hurdles for reimbursement at the American College of Cardiology annual meeting; will outcomes data save the day?

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS056730

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel